BlackBarn Capital Partners LP Reduces Stake in Arbutus Biopharma in Latest 13F Filing
BlackBarn Capital Partners LP Reduces Stake in Arbutus Biopharma in Latest 13F Filing
BlackBarn Capital Partners LP has made a notable adjustment to its portfolio, as revealed in its latest SEC 13F filing. The hedge fund reduced its holdings in Arbutus Biopharma (NASDAQ: ABUS), a company specializing in medical biology, by 150,000 shares. This move represents a minor decrease of 0.08% in its overall position size, reflecting a cautious rebalancing strategy.
Deep Dive into the Trade
As of the filing, BlackBarn Capital Partners LP holds a position in Arbutus Biopharma worth $8.9 million, which accounts for 3.19% of its total portfolio. This reduction brings the institution’s ownership of Arbutus Biopharma to 0.96% of the company’s total outstanding shares. Despite the reduction, the position remains a significant component of the fund’s portfolio, underscoring its continued interest in the medical biology sector.
Why Did BlackBarn Capital Partners Adjust Its Position?
The decision to reduce exposure to Arbutus Biopharma could be attributed to several factors, including sector-specific risks, valuation considerations, or broader portfolio rebalancing objectives. Given the dynamic nature of the medical biology industry, institutions like BlackBarn Capital Partners LP often fine-tune their positions to align with their investment strategies and market outlook.
How Much of Arbutus Biopharma Does BlackBarn Capital Partners Own?
Post-reduction, BlackBarn Capital Partners LP owns 0.96% of Arbutus Biopharma’s total shares, maintaining a meaningful stake in the company. This level of ownership reflects the institution’s ongoing confidence in the company’s potential, even as it trims its exposure.
Portfolio Impact
With Arbutus Biopharma representing 3.19% of BlackBarn Capital Partners LP’s portfolio, the stock remains a key holding despite the recent reduction. This adjustment highlights the fund’s strategic approach to balancing risk and opportunity within its investments.
For a deeper dive into BlackBarn Capital Partners LP’s investment strategies and historical 13F data, view BlackBarn Capital Partners LP’s full real-time portfolio and historical 13F data here.